Skip to main content

Table 2 Clinical data of PAH group

From: Loss of alveolar membrane diffusing capacity and pulmonary capillary blood volume in pulmonary arterial hypertension

Etiology of PAH n(%)

Ā 

Idiopathic

21(75%)

Heritable

3(10.7%)

Drug and toxin-induced

1(3.6%)

Associated with

3(10.7%)

NYHA class n(%)

Ā 

I

4(14%)

II

14(50%)

III

10(36%)

IV

0(0%)

Medications n(%)

Ā 

Prostacyclin

6(21.4%)

PDE5i

4(14.3%)

ERA

4(14.3%)

Prostacyclinā€‰+ā€‰PDE5i

4(14.3%)

Prsoatcyclinā€‰+ā€‰ERA

2(7.15%)

ERAā€‰+ā€‰PDE5i

2(7.15%)

Prostacyclinā€‰+ā€‰PDE5iā€‰+ā€‰ERA

6(21.4%)

6-MWD (m)

487Ā±24

Right ventricular systolic pressure (mmHg)

78 Ā±5

Mean pulmonary arterial pressure (mmHg)

52Ā±3

Mean pulmonary capillary wedge pressure (mmHg)

13Ā±1

Cardiac output (L/min)

6Ā±0.4

Cardiac index (L/min/m2)

3Ā±0.2

Pulmonary vascular resistance (wood units)

7.8Ā±0.9

  1. PAH: pulmonary arterial hypertension.
  2. NYHA: new york heart association.
  3. PDE5i: phosphodiesterase type 5 inhibitor.
  4. ERA: endothelin receptor antagonist.
  5. 6-MWD: 6 minute walk distance.